FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 403 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 How to Cope With Panic Attacks During Cancer July 12, 2022 Load more HOT NEWS FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... An existing blood test for ovarian cancer has been re-evaluated. The... Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab
